Analysts expect Retrophin Inc (NASDAQ:RTRX) to post earnings of ($0.27) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Retrophin’s earnings, with the highest EPS estimate coming in at $0.10 and the lowest estimate coming in at ($0.64). Retrophin posted earnings of $0.01 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 2,800%. The company is expected to announce its next earnings report on Thursday, May 3rd.
On average, analysts expect that Retrophin will report full year earnings of $0.09 per share for the current fiscal year, with EPS estimates ranging from ($0.77) to $0.94. For the next year, analysts forecast that the business will post earnings of $0.59 per share, with EPS estimates ranging from $0.33 to $0.85. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Retrophin.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.20). The business had revenue of $42.18 million for the quarter, compared to analyst estimates of $42.20 million. Retrophin had a negative return on equity of 13.98% and a negative net margin of 38.55%.
RTRX traded up $0.24 during midday trading on Monday, reaching $23.48. 264,786 shares of the company’s stock were exchanged, compared to its average volume of 234,780. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.74 and a current ratio of 3.80. Retrophin has a 1-year low of $15.55 and a 1-year high of $26.44.
Institutional investors and hedge funds have recently made changes to their positions in the business. Trexquant Investment LP acquired a new position in Retrophin during the third quarter worth about $203,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Retrophin in the third quarter valued at approximately $212,000. Teacher Retirement System of Texas acquired a new position in shares of Retrophin in the fourth quarter valued at approximately $256,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Retrophin in the third quarter valued at approximately $349,000. Finally, SG Americas Securities LLC raised its position in shares of Retrophin by 78.5% in the third quarter. SG Americas Securities LLC now owns 14,580 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 6,413 shares during the last quarter.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.